WuXi NextCODE Partners with Google Cloud

We’re delighted to announce an alliance between WuXi NextCODE and Google Cloud. This partnership will provide our customers and partners yet another world-class option for accessing a growing genomic data analysis toolset capable of fueling real breakthroughs in research and clinical care.

WuXi NextCODE is building the global standard platform for using genomic data at scale and over the internet. Our offerings already include our pioneering GOR database management system; our own secondary analysis pipeline; the Sequence Miner case-control research application; and the Clinical Sequence Analyzer interpretation system.  Google, meanwhile, has one of the world’s leading cloud platforms as well as its own outstanding genomics tools, such as BigQuery the DeepVariant secondary analysis pipeline, as well as full integration with other open-source tools that many are eager to leverage in tandem with ours.

As pioneers of using the genome online, working with Google in genomics is clearly exciting. Through this partnership, Google Cloud will host the entire suite of WuXi NextCODE’s core offerings and make these available on the Google Cloud Launcher Marketplace. This will provide users our combined IT horsepower and a full range of tools to perform at the leading edge of genomic research and clinical interpretation.  We expect to launch our tools on Google Cloud in May, at the BioIT World Conference & Expo in Boston.

As we build the global standard platform for genomic data, WuXi NextCODE has been making crucial partnerships to ensure our clients have the most options for accessing the full range of tools they need, however they prefer to do so.

Read more about this remarkable partnership at the WuXi NextCODE Genomics Insights blog or in our press release.  It is an important step towards realizing our vision to provide people and organizations with the best tools for using genomic data – wherever they are and at internet speed.


WuXi NextCODE Named one of the “Top 10 Most Innovative Companies in Biotech” by Fast Company for Creating the World’s Leading Platform for Genomic Data

One of fast company's most innovative companies 2018

Wuxi NextCODE has been named one of Fast Company’s “Top 10 Most Innovative Companies in Biotech” for being the world’s leading platform for storing, sharing, and interpreting massive sets of genomic data. With offices in Shanghai, Cambridge and Reykjavik, we provide the infrastructure underpinning many of the largest national genome projects and rare disease efforts underway worldwide.

One notable example of our capabilities cited by the editors of Fast Company is the RareCODE rare disease diagnostics platform we launched approximately one year ago in collaboration with Fudan Children’s Hospital in Shanghai. It’s hard to think of work that better taps, according to the magazine’s criteria, “both heartstrings and purse strings and uses the engine of commerce to make a difference in the world.”

RareCODE is the first platform that applies global gold standard genomics to the diagnosis of rare disease, at scale, in China. As a result of this program, Fudan Children’s has been able to quickly and accurately diagnose thousands of rare disease patients, allowing clinicians to optimize their treatment and care.

In just the first calendar year since its launch, RareCODE generated more than 12,000 clinical reports. We and our partners at Fudan also used it for some 2500 cases in their neonatal intensive care unit (NICU). We are now generating more than 1,000 new reports each month.  Thanks to this program, Fudan clinicians have been able to provide diagnoses to nearly 40% of patients tested and recommend treatment for nearly two-thirds of them. In short, this partnership is now carrying out sequencing and delivering diagnoses at a rate that is equivalent to that of the world’s leading laboratories.

We are delighted to join outstanding partners and colleagues on Fast Company’s Top Biotechs list, including Novartis, Biogen, GE Healthcare, Spark Therapeutics, and Sophia Genetics. The winners are selected by the magazine’s reporting team from thousands of enterprises reviewed each year.

Learn more about this award, and the breakthrough genomic platform that helped us earn it.

Genomic Power Tools: WuXi NextCODE Partners with 10x Genomics to Offer Advanced NGS Technologies

Genomics is advancing rapidly, and as the world’s only contract genomics organization, we make it our business to work closely with world-leading technology partners to make sure our customers can access all the best tools available for using the genome to derive the insights they need – from generating sequence data to storing it, querying it and sharing it, all in one place.

This week, 10x Genomics, Inc. announced new programs to deploy its innovative sequence data solutions to create a “global ecosystem of sequencing technologies and service providers who together span all aspects of the next-generation sequencing (NGS) workflow, from wet-lab to informatics,” said Edwin Hauw, senior director of strategic marketing at 10x Genomics, in their recent press release.  WuXi NextCODE is proud to be among the first partners in this strategy.

10x Genomics’ Certified Service Provider program will connect customers to a reliable network for outsourcing genomic and single cell analysis through global providers, leading off with WuXi NextCODE. The applications include 10x Genomics’ Chromium Single Cell Gene Expression, Immune Profiling Genome or Exome Solutions.

Their second initiative, Compatible Partnership Programs, will designate 10x compatible products, thereby helping customers identify ancillary NGS technologies that have been verified and validated as compatible with the company’s products. More details about the two new programs will be shared at this years’ Advances in Genome Biology and Technology Meeting (AGBT) held February 12 to 16 in Orlando, FL.

We at WuXi NextCODE already have considerable experience working with 10x Genomics. “We are proud to be among the first certified 10x service providers,” says Dr. Hongye Sun, WuXi NextCODE’s CTO and founder of our sequencing laboratory. “Our philosophy is to provide our customers with end-to-end solutions for using genomic data to improve health and medicine.

10x shares that vision, and their technology enables our customers to derive even more information and value from their sequencing data and to use other best-in-class laboratory tools and our informatics to generate novel insights. That’s the kind of innovation and collaboration that drives the field forward.”

It’s a strong partnership with a compelling rationale.  We at WuXi NextCODE are building the global standard platform for genomic data.  Our own capabilities include study design, sequencing, secondary analysis, storage, interpretation, scalable analytics, artificial intelligence and deep learning.

Meanwhile, as Sun says, “10x Genomics offers, among other tools, unique library methods in combination with short-read sequencing technologies that are very powerful for DNA/RNA sequencing from single cells to population scale. That means users can derive a range of key additional information, including on phasing, structural variation and gene expression. That will not be obtained with traditional short-read sequencing technologies alone.”

Once our partners have used 10x to generate the data they need, we are very pleased to be able to help them take it downstream according to their needs, to improve medicine and health around the world.


Louis Yuan Joins WuXi NextCODE to Lead Growth of China Businesses

Louis Yuan will lead the growth of WuXi NextCODE’s China businesses, sales, and other operations based out of the company’s Shanghai site.

I’m pleased to announce that Louis Yuan has joined WuXi NextCODE‘s team as senior vice president and China General Manager based in Shanghai. This is a major milestone for us, since further expansion and commercialization of our genomics platform in China is one of our strategic priorities, and Louis is the ideal person to lead that charge.

He has a stellar record of commercial success, scaling businesses, and managing sales teams more than 300 strong. He has also achieved multiple triple-digit revenue ramps in the past. Further, his experience supports our broader mandate as a fully integrated contract genomics organization (CGO) building the global standard platform for genomic data.

Among Louis’ outstanding accomplishments: He has held senior sales and marketing positions at such renowned businesses as Becton Dickinson, Sanofi Pasteur, and Pfizer, where he led the company’s launch of the blockbuster vaccine, Prevenar, in China.

For the complete announcement about his appointment and its significance, read more in our press release.